conclusions there was insignificant correlation between serum hepcidin and ferritin levels in the two groups of patients with tm and ti. it seems that regulation of hepcidin in patients with thalassemia is more affected by erythropoeitic activity than iron stores. also, hepcidin levels were significantly higher in patients with tm than ti, possibly due to higher erythropoeitic activity in ti. i...

Background: &beta-thalassemia is the most common monogenic disorder in human. The (CT) polymorphism at -158 upstream region of the &gammaG-globin gene and pharmacological factors such as hydroxyurea have been reported to influence &gamma-globin gene expression and the severity of clinical symptoms of &beta-thalassemia. Methods: In the present study, 51 &beta-thalassemia intermediate patients w...

introduction: patients referred to as having thalassemia major are usually those who come to medical attention in the first year of life and subsequently require regular transfusions to survive. those who present later or who seldom need transfusions are said to have thalassemia intermediahydroxyurea, an s-phase-specific and non-dna-hypomethylating chemotherapeutic agents is capable of inducing...

BACKGROUND Albuminuria is an early manifestation of sickle cell nephropathy. Prior small case series suggests benefit of hydroxyurea in reducing albuminuria, with a similar trend noted in pediatric studies. We aimed to comprehensively evaluate hydroxyurea use and prevalence of albuminuria in adult sickle cell patients. METHODS We performed a cross-sectional study of 149 adult patients followe...

is currently used in the treatment of various neoplastic and non-neoplastic diseases such as cancer, sickle cell anemia and HIV (1). Derivatives of hydroxyurea were found to inhibit matrix zinc metaloproteinases (MMP), urease, carboanhydrase, carboxypeptidase, cyclooxygenase and 5-lipooxygenase. Early experiments on antibacterial properties and effects on tumor cell lines of hydroxyurea and low...

Hydroxyurea, an antineoplastic drug, is a model teratogen. The administration of hydroxyurea to CD1 mice on gestation day 9 induces oxidative stress, increasing the formation of 4-hydroxy-2-nonenal adducts to redox-sensitive proteins such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the caudal region of the embryo. GAPDH catalytic activity is reduced, and its translocation into the nu...

Hydroxyurea is a newly approved therapeutic agent for the treatment of sickle-cell disease. Hydroxyurea reduces the number of painful crises in sicklecell patients presumably by increasing the levels of fetal hemoglobin, which has a large solubilizing effect on sickle-cell hemoglobin and reduces polymerization (1). Despite being used to treat a number of cancers for nearly 30 years, the mechani...

Combinations of inhibitors directed at the individual components of ribonucleotide reductase were studied for their effects on L1210 cell growth in culture. The combinations included pyrozoloimidazole (IMPY) plus deoxyadenosine and hydroxyurea plus deoxyadenosine. Modulators were utilized to potentiate the effects of hydroxyurea, IMPY, or deoxyadenosine. Desferal was used to modulate the activi...

Hydroxyurea is a cell-cycle-specific drug that has been used to treat myeloproliferative diseases and sickle cell anemia. We have recently shown that hydroxyurea, like nitric oxide (NO)-donor compounds, increased cGMP levels in human erythroid cells. We show now that hydroxyurea increases endothelial-cell production of NO; this induction of NO in human umbilical vein endothelial cells (HUVECs) ...

Hydroxyurea has proven efficacy in children and adults with sickle cell anemia (SCA), but with considerable inter-individual variability in the amount of fetal hemoglobin (HbF) produced. Sibling and twin studies indicate that some of that drug response variation is heritable. To test the hypothesis that genetic modifiers influence pharmacological induction of HbF, we investigated phenotype-geno...